



LucidQuest Intelligence
Accelerate your success





EAS 2025 – General Overview

- ➔ • **Redefining Cardiovascular Prevention:** A shift toward earlier and more aggressive management of **lipid and inflammatory risk factors**
- ➔ • **Integration of Cardiometabolic Care:** A unified approach to managing **dyslipidemia, type 2 diabetes, and obesity** together
- ➔ • **Expansion of Non-Statin Therapies:** Broad discussion on emerging **LDL-C and Lp(a)** lowering agents beyond traditional statins
- ➔ • **Translational Breakthroughs:** Novel insights into how basic science findings are being rapidly translated into **therapeutic candidates**
- ➔ • **Focus on Residual Risk:** Targeting **inflammation, triglycerides, and lipoprotein(a)** as key remaining drivers of **CVD events**
- ➔ • **Young Investigator Empowerment:** Significant spotlight on early-career researchers in **lipidomics, vascular biology, and metabolic disease**
- ➔ • **Hybrid Global Access:** Virtual and on-site participation expanded **global engagement**, fostering real-time worldwide collaboration
- ➔ • **Sustainability and Planetary Health:** New emphasis on environmental impacts of **cardiometabolic diseases** and the role of **planetary health** in cardiovascular prevention



EAS 2025– Conference Themes (1/2)



- **Targeting Lipoprotein(a) and Residual Cardiovascular Risk:** Breakthroughs in RNA therapies aimed at Lp(a) reduction and residual risk mitigation
- **Inflammation as a Therapeutic Target:** Novel anti-inflammatory agents explored beyond lipid-lowering, including NLRP3 and IL-1 β inhibition
- **Next-Generation Lipid-Lowering Therapies:** Advances in oral PCSK9 inhibitors, ANGPTL3 inhibitors, and small interfering RNA approaches
- **Cardiometabolic Disease Intersection:** Integrated strategies addressing dyslipidemia, type 2 diabetes, NAFLD, and obesity as interlinked conditions
- **Omics-Driven Precision Medicine:** Application of lipidomics, proteomics, and polygenic risk scores to individualize prevention and treatment



EAS 2025– Conference Themes (2/2)



- **Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Outcomes:** Emerging data recognizing NAFLD as a major independent driver of cardiovascular disease
- **Gut Microbiome and Atherosclerosis:** Exploration of microbiome-derived metabolites influencing lipid metabolism and vascular inflammation
- **Real-World Data and Pragmatic Cardiovascular Trials:** Emphasis on integrating registry studies and real-world cohorts to validate clinical trial findings
- **New Horizons in RNA and Gene Editing Therapies:** Updates on CRISPR/Cas9 and antisense technologies for genetically inherited lipid disorders
- **Diversity, Equity, and Representation in CVD Research:** Strong calls for improving trial diversity across race, ethnicity, and sex to enhance generalizability

Noteworthy Scientific presentations at EAS 2025





Key Topics From Notable Presentations (1/4)



• Lipid-Lowering Therapies:

- The lipid-lowering landscape will evolve with **siRNA therapies**, **novel PCSK9 inhibitors**, and **fixed-dose regimens** driving **personalized care**. **Real-world data** will highlight **treatment disparities** and inform future guideline refinement



• Atherosclerosis Pathogenesis and Therapy:

- Atherosclerosis research will expand with **novel immune, genetic, and metabolic insights**, enhancing **early detection** and enabling **targeted interventions** to halt or reverse **vascular disease progression**



• Cardiovascular Risk and Treatment Strategies:

- Pharmacologic innovation in cardiovascular care will focus on **SGLT2 inhibitors**, **RNA-based therapies**, and **lipoprotein(a) modulation**, while **genomic and sex-specific insights** will drive **individualized risk assessment** and **therapeutic precision**



Key Topics From Notable Presentations (2/4)



• Diabetes and Metabolic Syndrome:

- The conference will highlight the interplay between type 2 diabetes, obesity, and cardiovascular risk, showcasing data on arterial stiffness, plaque burden, liver dysfunction, and systemic inflammation. Novel biomarkers, real-world pharmacotherapies, and cell-based models will be presented to improve management of metabolic-associated diseases across diverse populations



• Clinical Trials and Real-World Studies:

- The conference will highlight early intensive lipid-lowering strategies, universal pediatric screening initiatives, and emerging biomarkers such as Lp(a), remnant cholesterol, and apolipoprotein variability to improve cardiovascular risk prediction and prevention outcomes across diverse populations



Key Topics From Notable Presentations (3/4)

- **Genetics and Genomics:**

- The conference will highlight innovative **cardiovascular genetic research**, featuring **gene therapy**, **transcriptomics**, and **functional screening** that refine diagnosis and introduce **next-gen therapeutics** for **lipid** and **arterial disorders**

- **Heart Disease and Heart Failure:**

- Integrating **biomarker discovery**, **immune modulation**, and **advanced imaging** is transforming **post-MI care** by personalizing **risk prediction** and enabling targeted **anti-inflammatory** and **metabolic interventions**.

- **Cardiovascular Imaging and Diagnostics:**

- Cardiovascular diagnostics will be transformed by **next-generation imaging modalities** and **functional assessments**, offering **early, non-invasive insights** into **disease activity**, **risk stratification**, and **treatment planning**



Key Topics From Notable Presentations (4/4)

- **Inflammation and Immune Mechanisms:**

- Chronic **vascular inflammation** remains central to **atherosclerosis**, with new strategies focusing on **immune modulation**, **lipid metabolism**, and **transcriptomic profiling** to identify **risk** and guide **anti-inflammatory therapies**

- **Other studies:**

- **Atherosclerosis management** will shift toward **precision interventions** using **gene-editing**, **proteomics**, and **targeted therapeutics**, while **clinical inertia** and **prevention gaps** will be addressed by **nationwide strategies** and **real-world trials**



Focus of Key Industry Sponsored Sessions at EAS 2025 (1/2)

- **Menarini Group:**

- Focus Areas: CETP Inhibition & Dyslipidemia Management
- Presentations will examine novel CETP inhibitors, their biological underpinnings, clinical potential in addressing cardiometabolic risk, and strategies to fill current gaps in lipid disorder management

- **Ultragenyx:**

- Focus Areas: Homozygous Familial Hypercholesterolaemia (HoFH) & Evinacumab Therapy
- Sessions will highlight diagnostic gaps in HoFH, real-world insights from the HICC registry, and comprehensive efficacy and safety data on evinacumab across pediatric and adult populations

- **Amarin:**

- Focus Areas: Icosapent Ethyl (EPA) in Cardiovascular Risk Reduction
- Sessions will focus on clinical outcomes from REDUCE-IT, mechanistic insights into EPA's action, and how emerging evidence supports expanding guideline recommendations for icosapent ethyl in ASCVD prevention



Focus of Key Industry Sponsored Sessions at EAS 2025 (2/2)

- **Daiichi Sankyo:**

- Focus Areas: Lipid-Lowering Strategies & Real-World Evidence
- Sessions will address oral lipid-lowering therapies for high-risk patients, real-world data from the MILOS study, and the role of combination therapy in optimizing lipid management outcomes across diverse populations

- **Chiesi:**

- Focus Areas: Comprehensive Management of HoFH in the UK
- Sessions will explore strategies for achieving LDL-C targets, optimizing long-term outcomes in adult HoFH, and utilizing real-world data to personalize care and reduce disease burden in the UK setting



Notable Presentations information at EAS 2025

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (1/8)



Date	Author	Title
05 May 2025	Ekaterina Polyakova	<u>ADDITIONAL CLINICAL POTENTIAL OF INCLISIRAN FOR PATIENTS WITH CHRONIC KIDNEY DISEASE</u>
05 May 2025	Shoaib Afzal	<u>LIPID-LOWERING TREATMENT IN WOMEN AND MEN WITH FAMILIAL HYPERCHOLESTEROLAEMIA FROM 1996 THROUGH 2021: A DANISH NATIONWIDE STUDY</u>
05 May 2025	Ali Altebainawi	<u>DO TWICE YEARLY INCLISIRAN VERSUS TWICE MONTHLY EVOLOCUMAB HAVE A HIGHER ADHERENCE RATE? A REAL-WORLD EVIDENCE FROM SAUDI ARABIA. (TWICE STUDY)</u>
05 May 2025	Andrea D'Amuri	<u>STATIN THERAPY IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: A POST-HOC ANALYSIS OF T.O.S.C.A. REGISTRY</u>
05 May 2025	Inhar Esnaola	<u>PLAQUE INSTABILITY AND STATIN THERAPY: A RETROSPECTIVE INSIGHT INTO CRYPTOGENIC ISCHEMIC STROKE</u>
05 May 2025	Cristina Gavina	<u>PREVALENCE OF STATIN INTOLERANCE IN A SELECTED POPULATION FROM INTEGRATED CARE UNITS: AN EMULATION OF THE CLEAR OUTCOMES TRIAL</u>
05 May 2025	Ruben Mijster	<u>VIEWS ON LIPID-LOWERING MEDICATION AND TREATMENT DECISIONS AMONG STATIN-INTOLERANT PATIENTS AND PATIENTS USING STATINS WHO RECEIVE PCSK9 INHIBITORS</u>
05 May 2025	Matthew Waite	<u>REAL-WORLD EXPERIENCE OF INCLISIRAN UP TO 27 MONTHS FROM INITIATION</u>
05 May 2025	In-Ho Yang	<u>CLINICAL OUTCOMES OF FIXED DOSE COMBINATION THERAPY OF LOW INTENSITY ROSUVASTATIN AND EZETIMIBE ON LIPID PROFILES IN HYPERCHOLESTEROLEMIA PATIENTS</u>

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (2/8)



Date	Author	Title
05 May 2025	Marta Biolo	<u>REAL-WORLD EXPERIENCE OF EFFICACY AND SAFETY OF EVINACUMAB IN COMBINATION WITH LOMITAPIDE THERAPY IN PAEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA</u>
05 May 2025	Simone Mattivi	<u>EFFICACY AND ADVERSE EVENTS OF THE USE OF BEMPEDOIC ACID IN A REAL-LIFE POPULATION</u>
05 May 2025	Camilla Portinari	<u>REAL-WORLD EXPERIENCE OF EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: CHECKMATE TO SEVERE HYPERCHOLESTEROLEMIA?</u>
05 May 2025	Luigi Junior Valletta	<u>THE EFFICACY OF BEMPEDOIC ACID THERAPY IN NO-TARGET PATIENTS TREATED WITH PCSK9 INHIBITORS</u>
05 May 2025	Yusuf Ziya Sener	<u>AN INSIGHT TO THE STATUS AND IMPACT OF STATIN USE IN CANCER PATIENTS WITH CORONARY ARTERY DISEASE</u>
05 May 2025	Jacob Christensen	<u>COMPREHENSIVE LIPID AND METABOLITE PROFILING OF LONG-TERM SURVIVORS OF TYPE 1 DIABETES COMPARED TO HEALTHY CONTROLS: CROSS-SECTIONAL RESULTS FROM THE DIALONG STUDY IN NORWAY</u>
05 May 2025	Deniz Demirci	<u>COMPARISON OF THE RELATIONSHIP BETWEEN LIPID PARAMETERS AND AGE AT FIRST ACS IN BOTH GENDERS</u>
05 May 2025	Florian Abel	<u>SEBELIPASE ALFA TREATMENT RESULTS IN SUSTAINED IMPROVEMENT OF LIPID PARAMETERS IN SYMPTOMATIC PEDIATRIC AND ADULT LAL-D PATIENTS: LONGITUDINAL DATA FROM THE INTERNATIONAL LAL-D REGISTRY</u>
05 May 2025	Maxima Mendez Castillo	<u>FROM GENES TO HYPERCHOLESTEROLEMIA: THE BENEFITS OF INCLISIRAN THERAPY FOR GCKR POLYMORPHISMS IN A STATIN-INTOLERANT PATIENT – A CLINICAL CASE</u>

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (3/8)



Date	Author	Title
05 May 2025	Laila Tata	<u>USING PRIMARY CARE DATA TO IDENTIFY SOCIODEMOGRAPHIC INEQUALITIES IN AGE AT STARTING LIPID-LOWERING THERAPY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA: A POPULATION-BASED ENGLAND-WIDE COHORT STUDY</u>
05 May 2025	Laila Tata	<u>EXPANDING THE UNITED KINGDOM PAEDIATRIC FAMILIAL HYPERCHOLESTEROLAEMIA REGISTER FOR NEW EVIDENCE TO SUPPORT GUIDELINES ON LIPID LOWERING THERAPIES FOR CHILDREN WITH FH</u>
05 May 2025	Rano Alieva	<u>THE IMPACT OF ONE-YEAR INCLISIRAN TREATMENT ON ACHIEVING TARGET LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PATIENTS WITH CHRONIC CORONARY SYNDROME.</u>
05 May 2025	Akshyaya Pradhan	<u>UPFRONT HIGH-INTENSITY LIPID-LOWERING THERAPY WITH ROSUVASTATIN AND EZETIMIBE FOR UNCONTROLLED DYSLIPIDEMIA IN INDIAN ASCVD PATIENTS: A REAL-WORLD STUDY (HILL II - INDIA STUDY)</u>
05 May 2025	Nadia Stancheva - Hristova	<u>INCLISIRAN TREATMENT AT UMHAT "DR. GEORGI STRANSKI" – PLEVEN, BULGARIA</u>
05 May 2025	Lorena Corso	<u>EVOLOCUMAB: EVALUATION OF EFFICACY IN LDL CHOLESTEROL REDUCTION, CARDIOVASCULAR OUTCOMES AND TOLERABILITY IN REAL-WORLD PATIENTS</u>
05 May 2025	Fadlina Chany Saputri	<u>BRAZILIN MODULATES PCSK9 EXPRESSION VIA INHIBITION OF UPSTREAM TRANSCRIPTIONAL REGULATORS IN HEPG2 CELLS</u>
05 May 2025	Raffaele Buganza	<u>TREATMENT EFFECTS OF EZETIMIBE IN CHOLESTERYL ESTER STORAGE DISEASE</u>
05 May 2025	Javier Ena	<u>EFFECT OF INCLISIRAN ON LIPOPROTEIN(A) VALUES: A META-ANALYSIS</u>

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (4/8)



Date	Author	Title
05 May 2025	Gabriela Berg	<u>COMPARISON OF DIFFERENT ESTIMATORS AND DIRECT HOMOGENEOUS ASSAY OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN A LARGE SOUTH AMERICAN POPULATION</u>
05 May 2025	Javier Ena	<u>REAL WORLD INCLISIRAN EFFICACY AND SAFETY: A META-ANALYSIS</u>
05 May 2025	Iain Jones	<u>QUANTITATIVE DATA COMPARING LDL RESULTS PRODUCED BY LIPID ULTRACENTRIFUGATION WITH THOSE CALCULATED BY THE SAMPSON EQUATION</u>
05 May 2025	Derek Stouth	<u>TREATING HYPERLIPIDEMIA BY TARGETING IP3R1 TO LOWER PCSK9 EXPRESSION AND SECRETION</u>
05 May 2025	Martina Ugolotti	<u>INVESTIGATING PCSK9 INHIBITION AS POTENTIAL STRATEGY IN ALZHEIMER'S DISEASE</u>
05 May 2025	Simone Bini	<u>ANGPTL3 AND PCSK9 LEVELS REGULATE THE CELLULAR BALANCE BETWEEN LIPOLYSIS AND LIPOGENESIS THROUGH STAT3</u>
05 May 2025	Ozcan Basaran	<u>GENDER DISPARITIES IN THE MANAGEMENT OF LIPID-LOWERING THERAPY FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE EPHEBUS STUDY</u>
05 May 2025	Marianne Klevmoen	<u>WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA RECEIVE LESS LIPID-LOWERING TREATMENT AND ARE DIAGNOSED TOO LATE: RESULTS OF A SURVEY OF WOMEN WITH FH ACROSS THE WORLD</u>
05 May 2025	Maria Boufounas	<u>DISCREPANCIES IN LDL-C ESTIMATION: A COMPARISON OF FRIEDEWALD, SAMPSON, AND MARTIN-HOPKINS EQUATIONS IN HIGH-RISK POPULATIONS</u>

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (5/8)



Date	Author	Title
05 May 2025	Shaoshuai Mao	<u>OPTIMIZATION OF EPIGENETIC REGULATORS FOR EFFICIENT AND LONG-LASTING SILENCING OF PCSK9 IN NON-HUMAN PRIMATES</u>
05 May 2025	Thomas Vanassche	<u>USAGE OF BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE IN BELGIAN PATIENTS WITH DYSLIPIDAEMIA: BASELINE CHARACTERISTICS AND 8-WEEK FOLLOW-UP DATA FROM THE MILOS STUDY</u>
05 May 2025	Damiano D'Ardes	<u>COULD DOCTORS REDUCE STATIN INTOLERANCE WITH A "DOCEBO" EFFECT?</u>
05 May 2025	Alessandra Marengo	<u>EARLY TNF-ALPHA LEVELS SUPPRESSION BY UPSTREAM EVOLOCUMAB USE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION</u>
05 May 2025	Laia Blanco-Casoliva	<u>ATP-CITRATE LYASE INHIBITION BY BEMPEDOIC ACID PROTECTS AGAINST ABDOMINAL AORTIC ANEURYSM</u>
05 May 2025	Karen Hvid	<u>ELEVATED REMNANT CHOLESTEROL CONFERS HIGH RISK OF ASCVD WITHOUT PROMPTING LIPID-LOWERING THERAPY: AN UNMET MEDICAL NEED</u>
05 May 2025	Riccardo Mattia Ricciardi	<u>SLCO1B1 MUTATION IS A PREDISPOSITION FOR STATIN INTOLERANCE INDEPENDENTLY FROM FH MUTATION IN PATIENT WITH HYPERCHOLESTEROLEMIA</u>
05 May 2025	Rafael Graça	<u>REGULATORY VARIANTS IN LDLR AND PCSK9 PROMOTER AND 5'UTR: INVESTIGATING THE IMPACT IN FAMILIAL HYPERCHOLESTEROLAEMIA</u>
05 May 2025	Sining Xie	<u>RISK OF ADVERSE EVENTS FOR STATINS, EZETIMIBE, BEMPEDOIC ACID, PCSK9 INHIBITORS, AND THEIR COMBINATIONS IN PATIENTS WITH DYSLIPIDEMIA: A NETWORK META-ANALYSIS</u>

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (6/8)



Date	Author	Title
05 May 2025	Kausik K. Ray	<u>REAL WORLD INSIGHTS FROM THE UNITED KINGDOM ON 8-WEEK EFFECTIVENESS OF BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE IN PATIENTS WITH DYSLIPIDAEMIA</u>
05 May 2025	Juan P. Nogueira	<u>LIPID-LOWERING EFFICACY OF OBICETRAPIB: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS</u>
05 May 2025	Maurizio Aversa	<u>EVALUATING DYSLIPIDAEMIA TREATMENT WITH BEMPEDOIC ACID AND EZETIMIBE OVER 8 WEEKS IN THE ITALIAN COHORT OF THE MILOS OBSERVATIONAL STUDY</u>
05 May 2025	Klaus Parhofer	<u>PERSISTENCE AND DETERMINANTS OF THERAPY DISCONTINUATION WITH PCSK9 MONOCLONAL ANTIBODIES IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK: PERI-DYS</u>
05 May 2025	Thomas Stulnig	<u>REAL-WORLD PROSPECTIVE DATA FROM AUSTRIA ON BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE FOR THE TREATMENT OF DYSLIPIDAEMIA</u>
05 May 2025	Per Johanson	<u>EFFICACY AND SAFETY OF AZD0780, AN ORAL SMALL MOLECULE PCSK9 INHIBITOR FOR TREATMENT OF HYPERCHOLESTEROLEMIA: RESULTS FROM A PH2B RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL</u>
05 May 2025	Pam Taub	<u>INCLISIRAN AS MONOTHERAPY COMPARED WITH PLACEBO OR EZETIMIBE IN PATIENTS AT LOW TO BORDERLINE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: RESULTS FROM THE VICTORION-MONO RANDOMIZED CLINICAL TRIAL</u>
06 May 2025	Valeria Pecce	<u>FLUORESCENT ORGANOID-BASED SYSTEM FOR MONITORING LONG-TERM TOLERANCE OF RNA-BASED THERAPIES: THE EXAMPLE OF ANGPTL3 AND PCSK9 SIRNAS ON HEPATIC ORGANOIDS.</u>
06 May 2025	Dirk J. Blom	<u>REAL-WORLD SAFETY AND EFFECTIVENESS OF LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA OVER TEN YEARS: DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER)</u>

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (7/8)



Date	Author	Title
06 May 2025	Jasmine Chebli	<u>LONG TERM MONITORING OF PATIENTS WITH PERSISTENT CHYLOMICRONEMIA TREATED WITH LPL GENE REPLACEMENT THERAPY WHO SUBSEQUENTLY RECEIVED PRECISION ADD-ON THERAPIES</u>
06 May 2025	Frederick J. Raal	<u>EFFICACY OF LERODALCIBEP, A THIRD GENERATION PCSK9 INHIBITOR, ACCORDING TO FH GENOTYPE IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</u>
06 May 2025	Elsa Franchi	<u>IMPACT OF WESTERN DIET AND PCSK9 ON THE EXPRESSION OF AMYOTROPHIC LATERAL SCLEROSIS-PREDISPOSING GENES</u>
06 May 2025	Jacob J. Christensen	<u>COMPREHENSIVE LIPID AND METABOLITE PROFILING OF YOUTH WITH CHILDHOOD ONSET TYPE 1 DIABETES COMPARED TO HEALTHY CONTROLS: RESULTS FROM THE NORWEGIAN ACD STUDY</u>
06 May 2025	Luís Masana-Marín	<u>LOMITAPIDE IN PAEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH) – ANALYSIS OF LONG-TERM (104-WEEK) SAFETY AND EFFICACY FROM THE APH-19 STUDY</u>
07 May 2025	Frederick J. Raal	<u>ZODASIRAN (ARO-ANG3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN LDL-CHOLESTEROL, APOLIPOPROTEIN B, AND ANGPTL3 IN PATIENTS WITH HOFH; GATEWAY FINAL RESULTS</u>
07 May 2025	Borge G. Nordestgaard	<u>LIPOPROTEIN(A) AND RECURRENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENTS BY SEX AND RACE/ETHNICITY AND USE OF LDL CHOLESTEROL LOWERING THERAPY: A COHORT STUDY FROM THE US FAMILY HEART DATABASE</u>
07 May 2025	Ethan J. Weiss	<u>A NOVEL ANGPTL4 INHIBITORY ANTIBODY SAFELY LOWERS PLASMA TRIGLYCERIDES AND REMNANT CHOLESTEROL IN HUMANS</u>
07 May 2025	Steven E. Nissen	<u>FIXED-DOSE COMBINATION OF OBICETRAPIB AND EZETIMIBE FOR LDL-C REDUCTION: A PHASE 3 RANDOMIZED TRIAL</u>

Notable Presentations information at EAS 2025

Lipid-Lowering Therapies (8/8)



Date	Author	Title
Virtual (On Demand)	Zeyad Bady	<u>EFFICACY AND SAFETY OF LOMITAPIDE, A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR, IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS</u>
Virtual (On Demand)	Yuliia Kovalchuk	<u>REGULAR DYNAMIC PHYSICAL ACTIVITY DURING THE OUTPATIENT PHASE OF CARDIAC REHABILITATION HELPS REDUCE PCSK9 LEVELS IN THE LONG TERM</u>

Notable Presentations information at EAS 2025

Atherosclerosis Pathogenesis and Therapy (1/4)



Date	Author	Title
05 May 2025	Justus Wettich	<u>MULTIMODAL DATASET INTEGRATION TO REDEFINE PLAQUE STABILITY IN HUMAN ATHEROSCLEROSIS</u>
05 May 2025	Rinkoo Dalan	<u>CAROTID ATHEROSCLEROSIS ASSOCIATES WITH INCIDENT CARDIOVASCULAR DISEASE IN MULTI-ETHNIC SINGAPORE</u>
05 May 2025	Jakub Wojtacha	<u>CIRCULATING MICRO-RNA IN THE ASSESSMENT OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME</u>
05 May 2025	Ying Jie Chee	<u>HAND GRIP STRENGTH IS ASSOCIATED WITH ARTERIAL STIFFNESS IN INDIVIDUALS WITH CARDIOMETABOLIC RISK FACTORS</u>
05 May 2025	Shangmei Shirley Lin	<u>ARTERIAL STIFFNESS IS INFLUENCED BY DIFFERENT CARDIOMETABOLIC RISK FACTORS</u>
05 May 2025	Jana Petrkova	<u>METHYLATION OF ADORA2A GENE IN PATIENTS WITH VASCULAR DISEASE (PILOT DATA)</u>
05 May 2025	Yasunori Sawayama	<u>LOW-DOSE ROSUVASTATIN PLUS EZETIMIBE VERSUS STANDARD-DOSE ROSUVASTATIN: THE EFFECT ON THE CAROTID ATHEROSCLEROSIS OF PATIENTS WITH HYPERCHOLESTEROLEMIA FOR TWO YEARS</u>
05 May 2025	Oliver Heaney	<u>MANIPULATION OF INTESTINAL MICROBIOTA AND POTENTIAL EFFECT ON EXPERIMENTAL ATHEROSCLEROSIS</u>
05 May 2025	Ece Yurtseven	<u>THE RELATIONSHIP OF HNP1-3, PCSK9, AND LP(A) WITH SUBCLINICAL ATHEROSCLEROSIS</u>

Notable Presentations information at EAS 2025

Atherosclerosis Pathogenesis and Therapy (2/4)



Date	Author	Title
05 May 2025	Elsayed Farag	<u>EGYPTIAN ASSOCIATION OF VASCULAR BIOLOGY AND ATHEROSCLEROSIS (EAVA) CONSENSUS ON THE USAGE OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS</u>
05 May 2025	Nemanja Vujić	<u>CONSEQUENCES OF LYSOSOMAL ACID LIPASE DEFICIENCY ON ATHEROSCLEROSIS DEVELOPMENT IN MICE</u>
05 May 2025	Noemí Rotllan	<u>LANDSCAPE OF LIPID UPTAKE FOR THE ESSENTIAL PROTEIN P116 OF THE HUMAN PATHOGEN MYCOPLASMA PNEUMONIAE: IMPLICATIONS FOR TROPISM TO ATHEROSCLEROTIC PLAQUES</u>
05 May 2025	Maria Boufounas	<u>MAXIMIZING THE POTENTIAL OF LP(A) IN VASCULAR RISK ASSESSMENT: AN OBSERVATIONAL ANALYSIS OF ITS UNDERUTILIZATION</u>
05 May 2025	Ewelina Jozefczuk	<u>SMOOTH MUSCLE CELL-DERIVED SPHINGOSINE KINASE 1 AS A KEY REGULATOR OF MYOGENIC TONE IN ANGIOTENSIN II-INDUCED HYPERTENSION</u>
05 May 2025	Estelle Ollivier	<u>ENDOTHELIAL P2X7 PROMOTES VENOUS THROMBOEMBOLISM</u>
05 May 2025	Yumeng Han	<u>TYROSINE KINASE INHIBITOR IMATINIB INDUCES LIPID ACCUMULATION VIA SREBP2 IN ENDOTHELIAL CELLS TO ENHANCE ATHEROSCLEROSIS</u>
05 May 2025	Agné Liuzé	<u>A NEW BIOMARKER FOR ATHEROSCLEROSIS: THE LINK BETWEEN VIMENTIN AND DEGREE OF ATHEROSCLEROSIS DEVELOPMENT</u>
05 May 2025	Piotr Szczepaniak	<u>VASCULAR EFFECTS OF CHEMOTHERAPY IN BREAST CANCER: EXPLORING PROTECTIVE EFFECTS OF ESTROGENS IN PREMENOPAUSAL WOMEN</u>

Notable Presentations information at EAS 2025

Atherosclerosis Pathogenesis and Therapy (3/4)



Date	Author	Title
05 May 2025	Joost Hoekstra	<u>HUMAN VASCULAR SMOOTH MUSCLE CELL CALCIFICATION FUELS ISODGR PRODUCTION: UNCOVERING A NEW MECHANISM IN ATHEROGENESIS.</u>
05 May 2025	Nuriiat Efendieva	<u>HIV-ASSOCIATED ATHEROSCLEROSIS. DATA RECEIVED BY OCT</u>
05 May 2025	Elsayed Farag	<u>PREDICTORS OF SUBCLINICAL ATHEROSCLEROSIS AND INCIPIENT MYOCARDIAL DYSFUNCTION IN ASYMPTOMATIC YOUNG HYPERTENSIVE SUBJECTS</u>
05 May 2025	Adriana Puente Barragán	<u>ATHEROGENIC DYSLIPIDEMIA AND MYOCARDIAL PERFUSION ABNORMALITIES IN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY: ¿DOES IT MATTER?.</u>
05 May 2025	Tomohiko Asakawa	<u>INTERLEUKIN-33 DEFICIENCY EXACERBATED ANGIOTENSIN II-INDUCED ABDOMINAL AORTIC ANEURYSMS BUT HAD NO EFFECT ON ANGIOTENSIN II-INDUCED ATHEROSCLEROSIS IN MALE APOLIPOPROTEIN E-DEFICIENT MICE.</u>
05 May 2025	Peter Jones	<u>SPLENIC TFH CELL LOCALISATION IN ATHEROSCLEROSIS</u>
05 May 2025	Daryna Katashynska	<u>THE ROLE OF IGM IN EFFEROCYTOSIS DURING ATHEROSCLEROSIS DEVELOPMENT</u>
05 May 2025	Dalgisio Lecis	<u>IDENTIFICATION OF A SELF-ANTIGEN SPECIFIC CD8+ T CELL POPULATION IN HUMAN CAROTID ATHEROSCLEROTIC PLAQUES</u>
05 May 2025	Aishvarya Prabhu	<u>ROLE OF LYMPHOCYTE GPR18 SIGNALING IN ATHEROSCLEROSIS</u>

Notable Presentations information at EAS 2025

Atherosclerosis Pathogenesis and Therapy (4/4)



Date	Author	Title
05 May 2025	Xueming Zhang	<u>B CELL RESPONSES IN THE CONTEXT OF ATHEROSCLEROSIS: A REASSESSMENT</u>
05 May 2025	Alessandro Scalia	<u>DEVELOPMENT OF A MICROFLUIDIC MODEL TO MIMIC THE ATHEROSCLEROSIS INITIATION PROCESS UNDER BREAST CANCER CELL EXPOSURE</u>
05 May 2025	Lunnathaya Tapeng	<u>HEALING ATHEROSCLEROTIC PLAQUES: PROSTACYCLIN DRIVES CYCLIC-AMP-MEDIATED HUMAN MACROPHAGE GENE REGULATION</u>
05 May 2025	Kristina Dimitrova	<u>ATHEROSCLEROTIC PLAQUES FROM LEFT AND RIGHT CAROTID SHOW SIMILAR HISTOLOGICAL AND GENE EXPRESSION PROFILES</u>

Notable Presentations information at EAS 2025

Cardiovascular Outcomes & Risk Stratification (1/2)



Date	Author	Title
05 May 2025	Dilafruz Akhmedova	<u>EVALUATION OF THE EFFICACY OF TREATMENT USING SGLT2 INHIBITORS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION</u>
05 May 2025	Amir Askarinejad	<u>EFFICACY AND SAFETY PROFILE OF EMPAGLIFOZIN FOLLOWING ACUTE MYOCARDIAL INFARCTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>
05 May 2025	Massimiliano Ruscica	<u>RESULTS FROM AN ITALIAN SINGLE-CENTRE STUDY ON LP(A) LEVELS IN THE ACUTE CORONARY SYNDROME SETTING - INCREASED STEMI OCCURRENCE AND CORONARY COMPLEXITY</u>
05 May 2025	Maurizio Panarelli	<u>INCREASED LIPOPROTEIN (A) REQUESTING AS RESULTS OF CARDIOVASCULAR RISK GUIDELINES</u>
05 May 2025	Rosalinda Posadas-Sánchez	<u>MITOCHONDRIAL DNA COPY NUMBER (MTDNA-CN) IS ASSOCIATED WITH PREMATURE CORONARY ARTERY DISEASE IN MEXICAN INDIVIDUALS. RESULTS OF THE GEA STUDY</u>
05 May 2025	David Kallend	<u>LERODALCIBEP AND ADJUDICATED CARDIOVASCULAR EVENTS IN A PRE-DEFINED POOLED ANALYSIS OF THREE LARGE LONG TERM PHASE III STUDIES</u>
05 May 2025	Queenie Chan	<u>GLOBAL BURDEN OF HIGH-RISK CARDIOVASCULAR PATIENTS WITHOUT PRIOR MYOCARDIAL INFARCTION OR STROKE: VESALIUS-REAL – PRELIMINARY RESULTS FROM UNITED KINGDOM</u>
05 May 2025	Marte F. Van Der Bijl	<u>SIMILAR EFFICACY OF CHRONIC PHARMACOLOGICAL TREATMENT IN WOMEN AND MEN WITH ACUTE CORONARY SYNDROME: A META-ANALYSIS AND META-REGRESSION</u>
05 May 2025	James W. O'Brien	<u>EXAMINING THE EFFECTS OF RITUXIMAB ON THE BCR REPERTOIRE FOLLOWING ANTERIOR ST ELEVATION MYOCARDIAL INFARCTION</u>

Notable Presentations information at EAS 2025

Cardiovascular Outcomes & Risk Stratification (2/2)



Date	Author	Title
06 May 2025	Matteo Lemoli	<u>PROTEINS PREDICTING ARTERIAL STIFFNESS AND HIGH BLOOD PRESSURE AND THEIR ASSOCIATION WITH CARDIOVASCULAR OUTCOMES: RESULTS FROM UK BIOBANK.</u>
07 May 2025	Stephen J. Nicholls	<u>SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS AT HIGH CARDIOVASCULAR RISK</u>

Notable Presentations information at EAS 2025

Diabetes and Metabolic Syndrome (1/4)



Date	Author	Title
05 May 2025	Woohyeun Kim	<u>EXPLORING THE LINK BETWEEN OBESITY AND ATHEROSCLEROTIC LIPID BURDEN: INSIGHTS FROM NIRS-IVUS AND BIA MEASUREMENTS</u>
05 May 2025	Ying Jie Chee	<u>NEUTROPHIL-LYMPHOCYTE RATIO IS ASSOCIATED WITH ALL-CAUSE MORTALITY AND INCIDENT CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES MELLITUS</u>
05 May 2025	Rinkoo Dalan	<u>MOLECULAR PHENOTYPING OF OXIDATIVE STRESS WITH POINT-OF-CARE MICROSCALE MAGNETIC RESONANCE (MNMR) SYSTEM ASSOCIATES WITH DIABETES STATUS AND VASCULAR FUNCTION IN A MULTI-ETHNIC COHORT FROM SINGAPORE</u>
05 May 2025	Lamija Ferhatbegovic	<u>PREVALENCE AND IMPACT OF ATHEROSCLEROTIC COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A RETROSPECTIVE STUDY</u>
05 May 2025	Romain Meer	<u>ASSOCIATION BETWEEN CRURAL MEDIAL AND INTIMAL ARTERIAL CALCIFICATION PATTERNS WITH ARTERIAL STIFFNESS AND HFPEF IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS: THE CROSS-SECTIONAL EARLY-HFPEF STUDY</u>
05 May 2025	Ekaterina Ogurtsova	<u>ACTIVATED AND REGULATORY T-HELPERS AND BLOOD MONOCYTES IN PATIENTS WITH HFPEF AND TYPE 2 DIABETES MELLITUS</u>
05 May 2025	Sabrina Scilletta	<u>SLEEP QUALITY IN ELDERLY PATIENTS WITH TYPE 2 DIABETES: FROM GLYCEMIC CONTROL TO ANXIETY-DEPRESSIVE DISORDERS</u>
05 May 2025	Pil Sang Song	<u>DIABETES MELLITUS AND TRENDS IN SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION, 2011 TO 2020</u>
05 May 2025	Joseph Blais	<u>EFFECTIVENESS AND SAFETY OF STATINS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ACCORDING TO PREDICTED 10-YEAR QRISK3 SCORE</u>

Notable Presentations information at EAS 2025

Diabetes and Metabolic Syndrome (2/4)



Date	Author	Title
05 May 2025	Antonio Cutruzzolà	<u>SGLT2-I IMPROVE MASLD, JUST LIKE GLP1-RA: A REAL-WORLD STUDY.</u>
05 May 2025	Petr Nachtigal	<u>MONOCLONAL ANTIBODY TARGETING ENDOGLIN PREVENTS LIVER SINUSOIDAL ENDOTHELIAL INFLAMMATION AND FIBROSIS PROGRESSION IN MASH</u>
05 May 2025	Jae Hyoung Park	<u>CORRELATION BETWEEN VISCERAL FAT AND CORONARY ARTERY CALCIUM IN METABOLIC SYNDROME PATIENTS</u>
05 May 2025	Meredith Donaldson	<u>HOLISTIC MANAGEMENT OF MULTIMORBIDITY: A RETROSPECTIVE REVIEW OF COMORBID ASCVD, COPD, T2DM, AND CKD FROM 2020 TO 2024</u>
05 May 2025	Djamshid Payziev	<u>INFLUENCE OF LOW GLYCEMIC INDEX DIET ON BLOOD AGGREGATION STATE AND COAGULATION HEMOSTASIS IN PATIENTS WITH ATHEROSCLEROTIC CORONARY ARTERY DISEASE</u>
05 May 2025	Francesca Schinzari	<u>MIRABEGRON RELAXES ARTERIES OF HUMAN VISCERAL ADIPOSE TISSUE THROUGH ANTAGONISM OF ALPHA1-ADRENOCEPTORS</u>
05 May 2025	Sevda Aygun	<u>THE ROLE OF FLOW-MEDIATED DILATION IN ASSESSING CARDIOVASCULAR RISK AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A RETROSPECTIVE STUDY</u>
05 May 2025	Alexandr Ceasovschi	<u>LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN TYPE 2 DIABETES PATIENTS WITHOUT OPTIMAL GLYCEMIC CONTROL</u>
05 May 2025	Ágnes Diószegi	<u>RESULTS OF A SINGLE-CENTER RETROSPECTIVE STUDY COMBINING DMD TREATMENT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS</u>

Notable Presentations information at EAS 2025

Diabetes and Metabolic Syndrome (3/4)



Date	Author	Title
05 May 2025	Emilie Gaillard	<u>INDIVIDUALS WITH TYPE 2 DIABETES HAVE INCREASED CORONARY PLAQUE BURDEN AND PLAQUE PROGRESSION DURING 10-YEAR SERIAL CORONARY CT ANGIOGRAPHY FOLLOW-UP</u>
05 May 2025	Festina Kuci	<u>INVESTIGATING THE ROLE OF CELLULAR METABOLISM IN HEPATOCYTE AND ENTEROCYTE ON THE DEVELOPMENT OF STEATOSIS: FOCUS ON A BOTANICAL EXTRACT.</u>
05 May 2025	Hajnalka Lőrincz	<u>KALLISTATIN – A NEW BIOMARKER OF CARBOHYDRATE AND LIPID METABOLISM IN OBESITY AND TYPE 2 DIABETES</u>
05 May 2025	Hidekatsu Yanai	<u>EFFECTS OF ORAL SEMAGLUTIDE ON METABOLIC PARAMETERS AND RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES</u>
05 May 2025	Rano Alieva	<u>CARDIOMETABOLIC PROFILE IN PATIENTS WITH CORONARY ARTERY DISEASE AND NON-ALCOHOLIC FATTY LIVER DISEASE:</u>
05 May 2025	Alexandr Ceasovschi	<u>THE IMPACT OF OBESITY ON PATIENTS WITH CARDIOVASCULAR DISEASES</u>
05 May 2025	Wonjin Kim	<u>IMPACT OF THE COVID-19 OUTBREAK ON THE OCCURRENCE OF METABOLIC SYNDROME ACCORDING TO THE METABOLIC SYNDROME SEVERITY SCORE</u>
05 May 2025	Massimiliano Ruscica	<u>LP(A) LEVELS IN INDIVIDUALS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE</u>
05 May 2025	Mi-Seung Shin	<u>FACTORS INFLUENCING THE PRACTICE OF A HEALTHY LIFESTYLE FOR MANAGING METABOLIC SYNDROME</u>

Notable Presentations information at EAS 2025

Diabetes and Metabolic Syndrome (4/4)



Date	Author	Title
05 May 2025	Hyun-Jin Kim	<u>SEX-SPECIFIC IMPACT OF THE COVID-19 PANDEMIC ON METABOLIC SYNDROME PREVALENCE</u>
05 May 2025	Iryna Tverezovska	<u>INFLUENCE OF SELENIUM SUPPLEMENTATION ON LIPID EXCHANGE IN PATIENTS WITH METABOLIC-ASSOCIATED LIVER DISEASE</u>
05 May 2025	Jae Bin Seo	<u>THE IMPACT OF ARTERIAL STIFFNESS ON THE PERFORMANCE OF PERCUTANEOUS CORONARY INTERVENTION ACCORDING TO THE OBESITY</u>
05 May 2025	Jiyeon Park	<u>BROWNING OF PERIVASCULAR ADIPOSE TISSUE DURING EARLY ATHEROSCLEROSIS PROGRESSION: A CONTRAST TO CLINICAL ATHEROSCLEROSIS</u>
05 May 2025	Laura Comi	<u>METABOLOMIC AND FUNCTIONAL CHARACTERIZATION OF HUMAN CELL MODELS TO INVESTIGATE THE PATHOGENETIC MECHANISMS UNDERLYING OBESITY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE</u>
07 May 2025	Stefano Romeo	<u>CLINICAL STAGING TO GUIDE ACTIONABLE MANAGEMENT OF SYSTEMIC METABOLIC DISORDERS AND THEIR SEQUELAE: A EUROPEAN ATHEROSCLEROSIS SOCIETY CONSENSUS STATEMENT</u>
Virtual (On Demand)	Zeyad Bady	<u>EFFICACY OF PHARMACOTHERAPIES ON PEDIATRIC PATIENTS WITH METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS</u>

Notable Presentations information at EAS 2025

Clinical Trials and Real-World Studies (1/4)



Date	Author	Title
05 May 2025	Fabian Demeure	<u>OPTIMISING LIPID MANAGEMENT IN VERY HIGH-RISK PATIENTS: A RETROSPECTIVE STUDY ON THE IMPACT OF LIPIDOLOGIST-LED CARE</u>
05 May 2025	Renata Fasano	<u>A REAL-WORLD PROTOCOL OF EARLY USE OF TRIPLE LIPID LOWERING THERAPY IN ACS</u>
05 May 2025	Seung Hwan Han	<u>NON-DIABETIC OVERWEIGHT/OBESE PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION HAVE IMPROVED CLINICAL OUTCOMES: A 10-YEAR LONGITUDINAL FOLLOW-UP STUDY</u>
05 May 2025	Nitish Behary Paray	<u>A META-ANALYSIS EVALUATING DIASTOLIC DYSFUNCTION IN PATIENTS WITH SARCOIDOSIS USING TRANSMITRAL VELOCITY PARAMETERS</u>
05 May 2025	Caroline Marchand	<u>IMPACTS OF A 12-WEEK CARDIOVASCULAR REHABILITATION PROGRAM ON LIMB HEMODYNAMICS, MOBILITY AND QUALITY OF LIFE IN PATIENTS WITH SYMPTOMATIC ATHEROSCLEROTIC DISEASE: A PROSPECTIVE COHORT STUDY</u>
05 May 2025	Talal Warsi	<u>AORTIC VALVE REPLACEMENT (AVR) VERSUS CONSERVATIVE CARE IN PATIENTS WITH ASYMPTOMATIC AORTIC STENOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>
05 May 2025	Kevin Jon Williams	<u>RATES OF ATHEROSCLEROTIC CARDIOVASCULAR EVENTS AND THEIR MANAGEMENT IN A LONGITUDINAL COHORT OF DERMATOMYOSITIS PATIENTS WITH SKIN INVOLVEMENT</u>
05 May 2025	Marco Allegra	<u>LIPID LOWERING THERAPY AND CARDIOVASCULAR PREVENTION: A RETROSPECTIVE OBSERVATION AT A SPOKE EMERGENCY DEPARTMENT IN PADUA PROVINCE.</u>
05 May 2025	Jaime Garcia De Tena	<u>HOSPITAL ADMISSION FOR ANY CAUSE AS AN OPPORTUNITY TO IMPROVE LIPID CONTROL IN PATIENTS AT MODERATE TO VERY HIGH CARDIOVASCULAR RISK: A CROSS-SECTIONAL OBSERVATIONAL STUDY</u>

Notable Presentations information at EAS 2025

Clinical Trials and Real-World Studies (2/4)



Date	Author	Title
05 May 2025	Mayo Shimoyama	<u>CAN SELF-REPORTED LAUGHTER AND STRESS SCORES INFLUENCE COGNITIVE FUNCTION IN A JAPANESE GENERAL POPULATION? THE TANUSHIMARU STUDY</u>
05 May 2025	Felix Fath	<u>CHANGES AND FINDINGS IN REGISTRY PATIENTS AT FOLLOW-UP ASSESSMENT AT CARE HIGH</u>
05 May 2025	Rong Xian Chen	<u>EXPLORING GENDER DIFFERENCES IN THE ASSOCIATION OF HYPERTENSION, HYPERLIPIDEMIA, AND HYPERGLYCEMIA WITH PHYSICAL ACTIVITY IN TAIWAN: A POPULATION-BASED CROSS-SECTIONAL STUDY</u>
05 May 2025	Arrigo Cicero	<u>RELIABILITY OF DIFFERENT PLASMA APOLIPOPROTEIN B LEVELS ESTIMATING FORMULAS IN A LARGE COHORT OF SOUTH-EUROPEAN SUBJECTS</u>
05 May 2025	Mohammad Abusido	<u>ABSENCE OF STANDARD MODIFIABLE RISK FACTORS IN OBESE AND OVERWEIGHT INDIVIDUALS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A MIDDLE EASTERN COHORT STUDY</u>
05 May 2025	Natalia Etcheverry	<u>EVALUATION OF UNIVERSAL DYSLIPIDEMIA SCREENING IN ARGENTINEAN PEDIATRICS THROUGH ANONYMOUS SELF-COMPLETED ONLINE SURVEY</u>
05 May 2025	Akshyaya Pradhan	<u>A RETROSPECTIVE OBSERVATIONAL STUDY ON THE USAGE PATTERNS AND SAFETY OF FIXED-DOSE COMBINATION OF ROSUVASTATIN, ASPIRIN AND CLOPIDOGREL IN INDIAN PATIENTS WITH ACUTE CORONARY SYNDROME</u>
05 May 2025	Katarina Raslova	<u>AN OBSERVATIONAL STUDY LEVERAGING MANDATORY UNIVERSAL PEDIATRIC TOTAL CHOLESTEROL SCREENING IN SLOVAKIA</u>
05 May 2025	Aris Agouridis	<u>LIPOPROTEIN (A) AND PSORIASIS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS</u>

Notable Presentations information at EAS 2025

Clinical Trials and Real-World Studies (3/4)



Date	Author	Title
05 May 2025	Pimjai Anthanont	<u>PREVALENCE OF HIGH PLASMA LIPOPROTEIN(A) IN OBSTRUCTIVE CORONARY ARTERY DISEASE PATIENTS WITH WELL-CONTROLLED LOW-DENSITY LIPOPROTEIN CHOLESTEROL: RETROSPECTIVE STUDY</u>
05 May 2025	Janeni Jeevanathan	<u>SEX DIFFERENCES OF LIPOPROTEIN(A) IN INDIVIDUALS AGED 18-90 YEARS – A NATIONWIDE STUDY OF 149,000 INDIVIDUALS</u>
05 May 2025	Byung Jin Kim	<u>IMPACT OF COTININE-VERIFIED SMOKING STATUS ON CHANGES IN LIPOPROTEIN(A) LEVELS: FROM A LONGITUDINAL STUDY</u>
05 May 2025	Maurizio Panarelli	<u>LIPOPROTEIN (A) IN A COHORT PRESENTING WITH FEATURE OF FAMILIAL HYPERCHOLESTEROLAEMIA BUT NEGATIVE GENETICS</u>
05 May 2025	Laura Volpi	<u>EVINACUMAB TREATMENT OF CARDIOVASCULAR HIGH-RISK PATIENTS IN A REAL-WORLD SETTING</u>
05 May 2025	Frank Annie	<u>IMPACT OF PREOPERATIVE HEARTFLOW ASSESSMENT ON GRAFT FAILURE RATES FOLLOWING CORONARY ARTERY BYPASS GRAFTING: A RETROSPECTIVE COHORT STUDY</u>
05 May 2025	Pekka Karhunen	<u>PROTEOMICS ANALYSIS REVEALS ORAL BACTERIAL PROTEINS IN CORONARY CALCIFIED ATHEROMAS. TAMPERE SUDDEN DEATH STUDY</u>
05 May 2025	Yume Nohara-Shitama	<u>COMBINED SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1 AND HIGH-SENSITIVITY CRP PREDICT ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY IN A GENERAL POPULATION: THE UKU LONGITUDINAL STUDY</u>
05 May 2025	Victoria Mparnia	<u>STUDY OF THE EFFECT OF BRADYKININ B2 RECEPTOR ACTIVATION, IN THE MANAGEMENT OF HYPERCHOLESTEROLEMIA AND CARDIOVASCULAR RISK</u>



Notable Presentations information at EAS 2025

Clinical Trials and Real-World Studies (4/4)



Date	Author	Title
06 May 2025	Stephen J. Nicholls	<u>IMPACT OF ADJUNCTIVE LIPID-MODIFYING THERAPY IN CLEAR OUTCOMES TRIAL</u>
06 May 2025	Madlaina Costa-Scharplatz	<u>HOW COMMON IS ELEVATED LP(A) IN PREMATURE ASCVD PATIENTS? A REAL-WORLD STUDY USING A LARGE US ELECTRONIC HEALTH RECORD DATABASE</u>
06 May 2025	Hyung Joon Joo	<u>PREDICTORS OF HIGH LIPOPROTEIN(A) VARIABILITY: A MULTICENTER STUDY AND IMPLICATIONS FOR RISK STRATIFICATION</u>
06 May 2025	Beryl B. Cummings	<u>REAL-WORLD ANALYSIS OF THE ASSOCIATION OF REMNANT CHOLESTEROL LEVELS WITH MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE</u>
06 May 2025	Diane E. Macdougall	<u>CHOLESTEROL TREATMENT TRENDS FROM 2014-2023 IN 3 MILLION US INDIVIDUALS WITH ASCVD: A RETROSPECTIVE COHORT ANALYSIS USING THE FAMILY HEART DATABASE</u>
Virtual (On Demand)	Sofia Morini	<u>UNCONVENTIONAL RISK FACTORS IN CARDIOVASCULAR DISEASES: A POPULATION BASED ITALIAN COHORT STUDY</u>
Virtual (On Demand)	Ioannis Koutsaliaris	<u>EPA PROMOTES ANGIOGENESIS IN OECS MORE EFFECTIVELY THAN DHA. AN IN VITRO STUDY.</u>
Virtual (On Demand)	Muneeza Ijaz	<u>MORTALITY TRENDS AMONG DYSLIPIDEMIC PATIENTS WITH ARRHYTHMIA: A RETROSPECTIVE ANALYSIS OF THE IMPACT OF GENDER, ETHNICITY AND GEOGRAPHY IN USA FROM 1999-2022</u>

Notable Presentations information at EAS 2025

Genetics and Genomics (1/3)



Date	Author	Title
05 May 2025	Veronika Todorovová	<u>ASSOCIATION BETWEEN MALE MORTALITY AND GENETIC RISK SCORES ASSOCIATED WITH TRIGLYCERIDEMIA AND RISK OF MYOCARDIAL INFARCTION</u>
05 May 2025	Diego Cabrera	<u>UTILITY OF NGS IN THE GENETIC DIAGNOSIS OF HF AND SIMILAR LIPID DISORDERS: DESCRIPTIVE ANALYSIS OF A COHORT OF PATIENTS</u>
05 May 2025	Thivanka Manawadu	<u>DOES CAROTID INTIMA MEDIA THICKNESS HAVE A ROLE IN PREDICTING GENETIC FAMILIAL HYPERCHOLESTEROLAEMIA?</u>
05 May 2025	Drazen Perica	<u>GENETIC VARIANTS OF FAMILIAR HYPERCHOLESTEROLEMIA - SINGLE CENTER FIRST REPORT</u>
05 May 2025	Fouzia Sadiq	<u>NOVEL CREB3L3 VARIANT ASSOCIATED WITH SEVERE HYPERTRIGLYCERIDEMIA</u>
05 May 2025	Fang-I Hsieh	<u>THE ASSOCIATION OF GENETIC POLYMORPHISMS OF UCP1-UCP3 AND THE RISK OF POOR OUTCOME AT 1-MONTH POST-STROKE AMONG ISCHEMIC STROKE PATIENTS</u>
05 May 2025	Silvia Roda	<u>ATP CITRATE LYASE GENE SILENCING: IMPACT ON LIPID METABOLISM OF HEPATOCYTES</u>
05 May 2025	Claudia Monsalve-Arango	<u>FAMILIAL CHYLOMICRONEMIA WITH REDUCED LPL ACTIVITY AND NEGATIVE GENETIC TESTING: A CASE REPORT</u>
05 May 2025	Juan Nogueira	<u>A NOVEL HOMOZYGOUS VARIANT IN APOA5: A SERIAL CASES REPORTS OF FAMILIAL CHYLOMICRONEMIA SYNDROME FROM COLOMBIA</u>

Notable Presentations information at EAS 2025

Genetics and Genomics (2/3)



Date	Author	Title
05 May 2025	Janja Zupan	<u>GENE EXPRESSION OF COREGULATORS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN PATIENTS WITH CORONARY ARTERY DISEASE</u>
05 May 2025	Zhi Chng Lau	<u>DIFFERENTIAL GENE EXPRESSION ANALYSIS HIGHLIGHTS DISTINCT CORONARY ARTERY DISEASE PATHOGENESIS PATHWAYS RELATED TO TELOMERE LENGTH ATTRITION IN ARTERIAL WALL TISSUES AND GRANULOCYTES</u>
05 May 2025	Marianne Klevmoen	<u>CURRENT GUIDELINES RESULT IN EXTENSIVE PREGNANCY-RELATED OFF-TREATMENT TIME IN WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA</u>
05 May 2025	Aya A. Shouma	<u>ANALYSIS OF THE DIABETIC ARTERIAL TRANSCRIPTOME REVEALS NOVEL BIOMARKERS OF MACROVASCULAR DISEASE</u>
05 May 2025	Daniel Gaudet	<u>TRANSITION OF PATIENTS WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME FROM VOLANESORSEN TO OLEZARSEN: UPDATED INTERIM SAFETY AND PHARMACOKINETIC RESULTS</u>
05 May 2025	Maëlle C. Jan	<u>GENETIC SCREENING AND FUNCTIONAL ANALYSIS OF LIPA VARIANTS IN AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA</u>
06 May 2025	David Kallend	<u>PHASE 3 POOLED LONG-TERM SAFETY AND EFFICACY OF LERODALCIBEP IN PATIENTS WITH ASCVD, HEFH, VERY HIGH OR HIGH RISK FOR ASCVD</u>
06 May 2025	Jonviea Chamberlain	<u>THE EPIHEART SIGNATURE: AN EPIGENETIC BIOMARKER OF CARDIOVASCULAR DISEASE RISK</u>
06 May 2025	Jonviea Chamberlain	<u>CELL TYPE-SPECIFIC DIFFERENTIAL METHYLATION AND CARDIOVASCULAR RISK: INTEGRATION OF DECONVOLVED EPIGENETIC AND TRANSCRIPTOMIC SIGNALS</u>

Notable Presentations information at EAS 2025

Genetics and Genomics (3/3)



Date	Author	Title
06 May 2025	Samuel Gidding	<u>HYPOALBUMINEMIA GENETIC VARIANTS ARE ASSOCIATED WITH HIGHER CHOLESTEROL LEVELS BUT NOT ATHEROSCLEROTIC HEART DISEASE</u>
06 May 2025	Chenbo Xu	<u>AAV GENE THERAPY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: TRANSLATIONAL STUDIES AND EARLY PHASE I TRIAL INTERIM RESULTS</u>

Notable Presentations information at EAS 2025

Heart Disease and Heart Failure (1/4)



Date	Author	Title
05 May 2025	Kakha Nadaraia	<u>EFFECTIVENESS AND SAFETY OF EARLY ADMINISTRATION OF COLCHICINE IN PATIENTS WITH NON-ST-SEGMENT-ELEVATION MYOCARDIAL INFARCTION</u>
05 May 2025	Devendra Agrawal	<u>DIFFERENTIALLY EXPRESSED GENES IN THE REGULATION OF ECM REMODELING IN ARTERIOVENOUS FISTULA IN YUCATAN MINISWINE</u>
05 May 2025	Ting Ting Chang	<u>NITRIC OXIDE DONOR THERAPY IMPROVES ISCHEMIA-INDUCED NEOVASCULARIZATION IN CHRONIC KIDNEY DISEASE</u>
05 May 2025	Tatyana Storozhenko	<u>PROGNOSTIC VALUE OF BIOMARKERS IN ACUTE MYOCARDIAL INFARCTION WITH REDUCED GLOMERULAR FILTRATION RATE: A COMPARATIVE COHORT STUDY</u>
05 May 2025	Hosna Elshony	<u>SPINAL CORD ISCHEMIA SECONDARY TO AORTIC DISSECTION: CASE REPORT WITH LITERATURE REVIEW FOR DIFFERENT CLINICAL PRESENTATIONS, RISK FACTORS, RADIOLOGICAL FINDINGS, THERAPEUTIC MODALITIES, AND OUTCOME</u>
05 May 2025	Victor Gurevich	<u>EFFECTIVE MICROCIRCULATION AS AN ADAPTIVE FACTOR PREVENTING MYOCARDIAL ISCHEMIA IN HETEROZYGOUS HYPERCHOLESTEROLEMIA</u>
05 May 2025	Nagaisha Nagajothi	<u>USE OF EXTRA LONG SHEATH FOR TRANS-RADIAL CARDIAC CATHETERIZATION</u>
05 May 2025	Panagiotis Zachos	<u>ANTIPHOSPHOLIPID SYNDROME AND CARDIAC COMPLICATIONS</u>
05 May 2025	Hyun-Jin Kim	<u>EFFECT OF ESTIMATED PULSE WAVE VELOCITY ON LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE</u>

Notable Presentations information at EAS 2025

Heart Disease and Heart Failure (2/4)



Date	Author	Title
05 May 2025	Jan Kyselovic	<u>ATORVASTATIN IMPROVES CRITICAL LIMB ISCHEMIA BY ENHANCING ANGIOGENESIS VIA VEGF-A, HGF, AND IGF-1 MODULATION IN BONE MARROW-DERIVED MSCS</u>
05 May 2025	Qadeer Abdul	<u>EVALUATION OF ALTERED ECHOCARDIOGRAPHIC PARAMETERS FOR CANCER THERAPEUTICS-RELATED CARDIAC DYSFUNCTION IN PATIENTS WITH LYMPHOMA/LEUKEMIA AFTER ANTHRACYCLINE CHEMOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
05 May 2025	Ibrahim Nasser	<u>CAN ROUTINE ECHOCARDIOGRAPHIC PARAMETERS DETECT SUBTLE MYOCARDIAL DYSFUNCTION IN SARCOID PATIENTS? A META-ANALYSIS</u>
05 May 2025	Talal Warsi	<u>PRE-TREATMENT WITH ALLOPURINOL IN ACUTE MYOCARDIAL INFARCTION PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
05 May 2025	Baojun Zhong	<u>HIGH PLASMA MANNOSE-BINDING LECTIN (MBL) IS ASSOCIATED WITH INCREASED RISK OF HEART FAILURE AFTER AN ACUTE CORONARY SYNDROME – A PROSPECTIVE COHORT STUDY</u>
05 May 2025	Sandra Vladimirov Sopic	<u>TARGETED NMR METABOLOMICS REVEALS SEX-SPECIFIC MARKERS OF MYOCARDIAL INFARCTION</u>
05 May 2025	Loukianos Rallidis	<u>ON TREATMENT REMNANT CHOLESTEROL LEVELS ARE PREDICTIVE OF MYOCARDIAL INFARCTION AMONG PATIENTS WITH STABLE ISCHEMIC HEART DISEASE: DATA FROM LAERTES AND STAMINA REGISTRIES</u>
05 May 2025	Yong Fen Qi	<u>INTERMEDIN UP-REGULATES MITOCHONDRIAL SIRT3 TO ATTENUATE AGING-ASSOCIATED CARDIAC REMODELING BY RECEPTOR-MEDIATED SIGNALING PATHWAYS</u>
05 May 2025	Amna Arif	<u>ANTIPLATELET AND ANTICOAGULANT COMPOUND (APAC) RESTRICTS THROMBOINFLAMMATION TO AMELIORATES MYOCARDIAL ISCHEMIA REPERFUSION INJURY</u>

Notable Presentations information at EAS 2025

Heart Disease and Heart Failure (3/4)



Date	Author	Title
06 May 2025	Miron Sopić	<u>EXPLORING EPITRANSCRIPTOMIC LANDSCAPE OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN MYOCARDIAL INFARCTION</u>
06 May 2025	Xiaowei Li	<u>INHIBITION OF B CELL ACTIVATION BY IBRUTINIB IMPROVES CARDIAC FUNCTION IN EXPERIMENTAL MYOCARDIAL INFARCTION IN MICE</u>
06 May 2025	Loukianos Rallidis	<u>LIPOPROTEIN (A) LEVELS ABOVE 70 MG/DL ARE ASSOCIATED WITH MAJOR ADVERSE CARDIAC EVENTS IN SECONDARY PREVENTION: DATA FROM CALLINICUS-HELLAS REGISTRY</u>
Virtual (On Demand)	Yimeng Wang	<u>RELATIONSHIP BETWEEN STRESS HYPERGLYCEMIA RATIO OF ONE-YEAR MORTALITY IN PATIENTS WITH HEART FAILURE : ANALYSIS OF THE MIMIC-IV DATABASE.</u>
Virtual (On Demand)	Diana Kiseleva	<u>OSMOLALITY REMODELING EFFECT ON NEONATAL RAT CARDIOMYOCYTES MONOLAYERS</u>
Virtual (On Demand)	Alyena Golubeva	<u>NONINVASIVE PARAMETERS OF MYOCARDIAL WORK AND DIASTOLIC MYOCARDIAL FUNCTION IN THE ASSESSMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS</u>
Virtual (On Demand)	Alyena Golubeva	<u>THE RELATIONSHIP OF MYOCARDIAL DEFORMATION CHARACTERISTICS WITH HEART RATE VARIABILITY IN PATIENTS WITH STEMI</u>
Virtual (On Demand)	Tatyana Medvedeva	<u>GRANULOCYTE COLONY STIMULATING GROWTH FACTOR (G-CSF), GRANULOCYTE-MACROPHAGE COLONY STIMULATING GROWTH FACTOR (GM-CSF) IN THE PATHOGENESIS OF HEART FAILURE IN YOUNG MEN WITH GOUT</u>
Virtual (On Demand)	Olga Gruzdeva	<u>SPHINGOMYELINS PROFILE OF LOCAL HEART FAT DEPOTS IN PATIENTS WITH CORONARY ARTERY DISEASE AND HEART FAILURE</u>

Notable Presentations information at EAS 2025

Heart Disease and Heart Failure (4/4)



Date	Author	Title
Virtual (On Demand)	Sofia Dolmatova	<u>LEPTIN RESISTANCE IN PATIENTS WITH MYOCARDIAL INFARCTION AND ISCHEMIC HEART DISEASE</u>
Virtual (On Demand)	Nilufar Usmonova	<u>PSYCHOSOMATIC DISORDERS IN PATIENTS WITH CHRONIC HEART FAILURE AND ATRIAL FIBRILLATION</u>
Virtual (On Demand)	Margarita A Sazonova	<u>NEW MARKERS OF CORONARY HEART DISEASE WITH OLD MYOCARDIAL INFARCTION: CERTAIN VARIANTS OF RELATIVE LENGTH OF TELOMERIC REPEATS</u>
Virtual (On Demand)	Laylo Ilxomova	<u>THE ROLE OF MECHANICAL DISPERSION IN ASSESSING THE SEVERITY OF VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH CORONARY ARTERY DISEASE FOLLOWING LEFT VENTRICULAR MYOCARDIAL INFARCTION</u>
Virtual (On Demand)	Viktoria Stepanova	<u>ECHOCARDIOGRAPHIC PARAMETERS OF LEFT VENTRICLE REMODELING IN PATIENTS PAST MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION BEFORE AND AFTER MYOCARDIAL REVASCULARIZATION</u>

Notable Presentations information at EAS 2025

Cardiovascular Imaging and Diagnostics (1/3)



Date	Author	Title
05 May 2025	Qadeer Abdul	<u>IMPAIRED CARDIOVASCULAR FUNCTION ASSESSED BY DOPPLER ECHOCARDIOGRAPHY IN PATIENTS WITH MULTIPLE SCLEROSIS: A META-ANALYSIS</u>
05 May 2025	Mahmoud Eldesouky	<u>CLINICAL OUTCOMES OF COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY (CTCA) IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: A SINGLE-CENTRE EXPERIENCE</u>
05 May 2025	Rafail Kotronias	<u>COMPARATIVE EVALUATION OF PHOTON-COUNTING CCTA RELATIVE TO 3D QUANTITATIVE CORONARY ANGIOGRAPHY FOR CORONARY LUMINAL STENOSIS EVALUATION</u>
05 May 2025	Leonardo Portolan	<u>NON-INVASIVE PHOTON-COUNTING CCTA IMAGING OF SEVERELY CALCIFIC CORONARY ARTERY DISEASE: IS ULTRA-HIGH-RESOLUTION IMAGING THE SOLUTION?</u>
05 May 2025	Mohammad Abusido	<u>COMPARATIVE STUDY OF TWO DIFFERENT MIDDLE EASTERN POPULATIONS WITH CORONARY HEART DISEASE; PATIENTS WITH OVERT SYNDROMES AND PATIENTS DIAGNOSED BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY</u>
05 May 2025	Sanghyun Park	<u>HIGH BRACHIAL-ANKLE PULSE WAVE VELOCITY IS A RISK FACTOR FOR CARDIOVASCULAR EVENT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING INVASIVE CORONARY ANGIOGRAPHY: A MULTICENTER STUDY</u>
05 May 2025	Arianna Toscano	<u>CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ROLE OF NON-INVASIVE IMAGING AND TRADITIONAL RISK SCORES</u>
05 May 2025	Spyridon Simantiris	<u>CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY IN GREEK CLINICAL PRACTICE: DATA FROM A CONTEMPORARY, REAL-WORLD MULTICENTER COHORT [CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY – GREECE (COCOA-GR)]</u>
05 May 2025	Simon Williams	<u>DIFFERENCES IN PROTEIN CONCENTRATION BETWEEN SYSTEMIC BLOOD AND BLOOD FROM DISEASED CORONARY ARTERIES; EARLY INSIGHTS FROM THE BIOPATTERN TRIAL</u>

Notable Presentations information at EAS 2025

Cardiovascular Imaging and Diagnostics (2/3)



Date	Author	Title
05 May 2025	Sam Fry	<u>AUTOMATED QUANTITATIVE PLAQUE ANALYSIS FOR THE ASSESSMENT OF LARGE CCTA REGISTRY DATASETS</u>
06 May 2025	Paula Nogales	<u>18FDG-PET IMAGING REVEALS GLYCOLYTIC ACTIVITY AS A MARKER OF ATHEROSCLEROTIC DISEASE ACTIVITY</u>
06 May 2025	Ibrahim A. Nasser	<u>SPECKLE-TRACKING ECHOCARDIOGRAPHY DETECTS EARLY CHANGES IN LEFT VENTRICULAR MYOCARDIAL DEFORMATION MECHANICS IN PATIENTS WITH SARCOIDOSIS: A META-ANALYSIS</u>
06 May 2025	Nitish K. Behary Paray	<u>ASSESSMENT OF SUBCLINICAL MYOCARDIAL DEFORMATION INDICES AND SPECKLE TRACKING ECHOCARDIOGRAPHY ALTERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A META-ANALYSIS</u>
06 May 2025	Thomas Halborg	<u>EVALUATING CORONARY ARTERY INFLAMMATION BY ANALYSING PERI-CORONARY FAT ATTENUATION INDEX SCORE: INSIGHTS FROM POST-MORTEM CCTA AND HISTOPATHOLOGY</u>
06 May 2025	Yangyang Cheng	<u>CORRELATION BETWEEN MYOCARDIAL MICRO-ALTERATIONS AND INTRACRANIAL ATHEROSCLEROSIS IDENTIFIED BY HR- MRI IN MIDDLE-AGED OR OVER COMMUNITY DWELLING ADULTS</u>
Virtual (On Demand)	Toqeer Ahmed	<u>DETECTION OF MYOCARDIAL DAMAGE IN PATIENTS WITH CARDIAC SARCOIDOSIS VERSUS EXTRACARDIAC SARCOIDOSIS USING SPECKLE TRACKING ECHOCARDIOGRAPHY: A META-ANALYSIS</u>
Virtual (On Demand)	Alexander Vrublevsky	<u>DISTURBANCES OF THE THORACIC AORTA BIOMECHANICS IN DEGENERATIVE CALCIFIC AORTIC VALVE STENOSIS: 2D SPECKLE-TRACKING TRANSOESOPHAGEAL ECHOCARDIOGRAPHIC ASSESSMENT</u>
Virtual (On Demand)	Dmitriy Panfilov	<u>THORACIC AORTA BIOMECHANICS AFTER HEMIARCH REPAIR: 2D SPECKLE-TRACKING TRANSOESOPHAGEAL ECHOCARDIOGRAPHIC ASSESSMENT</u>

Notable Presentations information at EAS 2025

Cardiovascular Imaging and Diagnostics (3/3)



Date	Author	Title
Virtual (On Demand)	Henil Upadhyay	<u>CT IMAGING OF SUBCLINICAL ATHEROSCLEROSIS IN LIPID CLINICS: TIME TO STOP LIVING UNDER A ROCK</u>

Notable Presentations information at EAS 2025

Inflammation and Immune Mechanisms (1/4)



Date	Author	Title
05 May 2025	Federica Fogacci	<u>IMPACT OF TREATMENT WITH EVOLOCUMAB ON BIOMARKERS OF CHRONIC SYSTEMIC AND VASCULAR INFLAMMATION</u>
05 May 2025	Moustafa Morsy	<u>INFLAMMATORY MARKERS ARE ASSOCIATED WITH ISCHAEMIC STROKE AMONG INDIGENOUS AFRICANS: THE SIREN STUDY</u>
05 May 2025	Andisyah Putri Sekar	<u>CLINICAL OUTCOMES OF BLEEDING AND EMBOLISM IN PATIENTS USING ANTITHROMBOTIC AND ANTI-INFLAMMATORY DRUGS: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE</u>
05 May 2025	Fatemah Almarri	<u>INFLAMMATION-RELATED PLASMA PHENOTYPE: A NOVEL BIOMARKER OF ATHEROSCLEROSIS</u>
05 May 2025	Ljiljana Majnaric	<u>FACTORS INFLUENCING VARIATIONS OF THE INFLAMMATORY MARKER NLR IN PRIMARY CARE PATIENTS WITH T2D</u>
05 May 2025	Ljiljana Majnaric	<u>DIAGNOSTIC AND PROGNOSTIC RELEVANCE OF INFLAMMATORY MARKERS IN T2D PATIENTS</u>
05 May 2025	Guyu Zeng	<u>THE COMBINED AND MEDIATING PROGNOSTIC IMPACT OF INFLAMMATION AND STRESS HYPERGLYCEMIA IN DIABETIC AND NONDIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME</u>
05 May 2025	Florence Ottonnes	<u>PHENOTYPIC, METABOLIC, AND FUNCTIONAL CHARACTERIZATION OF EXPERIMENTAL MODELS OF FOAMY MACROPHAGES: TOWARD THERAPEUTIC RESEARCH IN ATHEROSCLEROSIS</u>
05 May 2025	Miran Šebeštjen	<u>INFLUENCE OF PCSK9 INHIBITORS ON GENE EXPRESSION OF INFLAMMATION AND HEMOSTASIS PARAMETERS IN PATIENTS WITH CORONARY ARTERY DISEASE</u>

Notable Presentations information at EAS 2025

Inflammation and Immune Mechanisms (2/4)



Date	Author	Title
05 May 2025	Nikolai Orekhov	<u>IMPROVING PROGNOSTIC SIGNIFICANCE OF LOW-DENSITY LIPOPROTEIN-CONTAINING CIRCULATING IMMUNE COMPLEXES IN ATHEROSCLEROSIS</u>
05 May 2025	Samuel Sherratt	<u>ADDITION OF EICOSAPENTAENOIC ACID (EPA) TO A GLP-1 AGONIST INCREASED EXPRESSION OF AN ENDOTHELIAL ANTIOXIDANT RESPONSE ELEMENT (ARE) PROTEIN IN A SYNERGISTIC FASHION DURING INFLAMMATION</u>
05 May 2025	Samuel Sherratt	<u>EICOSAPENTAENOIC ACID (EPA) AND A GLP-1 AGONIST CAUSED SYNERGISTIC CHANGES IN PROTEIN EXPRESSION AND MEDIATORS OF ENDOTHELIAL ENDOPLASMIC RETICULUM FUNCTION DURING INFLAMMATION</u>
05 May 2025	Xiaohan Zhang	<u>MODULATING PENTOSE PHOSPHATE PATHWAY TO ATTENUATE VASCULAR ENDOTHELIAL INFLAMMATION</u>
05 May 2025	Tuva Dahl	<u>M6A METHYLATION DYNAMICS IN STEMI: IL-6 INHIBITION AND IMMUNE MODULATION</u>
05 May 2025	Ingrid E. Dumitriu	<u>FRACTALKINE RECEPTOR CX3CR1 REGULATES MIGRATION OF CD4CD28NULL T CELLS IN HIGH-RISK ACUTE CORONARY SYNDROME PATIENTS</u>
05 May 2025	Ciarán Kennedy	<u>TIPPING THE BALANCE: INVESTIGATING THE POTENTIAL OF THE SPECIALISED PRO-RESOLVING MEDIATOR LIPOXIN-A4 TO MODULATE THE INFLAMMATORY LANDSCAPE IN ATHEROSCLEROSIS.</u>
05 May 2025	Agné Liuzé	<u>MARKERS OF INFLAMMATION, AS MEASURED BY A COMPLETE BLOOD COUNT, ARE ASSOCIATED WITH CORONARY ATHEROSCLEROSIS AND REFLECT ITS SEVERITY</u>
05 May 2025	Neil Macritchie	<u>DEFICIENCY IN THE INFLAMMATORY CHEMOKINE RECEPTORS 1,2,3 AND 5 ATTENUATES ATHEROSCLEROSIS IN MICE WHILE REDUCING AORTIC INFLAMMATORY MONOCYTE-MACROPHAGE CONTENT</u>



Notable Presentations information at EAS 2025

Inflammation and Immune Mechanisms (3/4)



Date	Author	Title
05 May 2025	Tomasz Mikolajczyk	<u>ROLE OF ATYPICAL CHEMOKINE RECEPTOR 2 IN HYPERTENSION.</u>
05 May 2025	Janneke W.C.M. Mulder	<u>INSIGHTS INTO THE ROLE OF TRIGLYCERIDES AND T CELLS IN CARDIOVASCULAR RISK: T CELLS OF PATIENTS WITH MODERATE HYPERTRIGLYCERIDEMIA HAVE A PRO-INFLAMMATORY TRANSCRIPTOMIC PROFILE</u>
05 May 2025	Goo Taeg Oh	<u>PCSK9 DEFICIENCY MITIGATES CARDIAC INFLAMMATION AFTER MYOCARDIAL INFARCTION VIA UPREGULATION OF ATRIAL NATRIURETIC PEPTIDE</u>
05 May 2025	Alexander N Orekhov	<u>GENE AND EPIGENETIC REGULATION IN VIOLATION OF THE INFLAMMATORY RESPONSE IN ATHEROSCLEROSIS</u>
05 May 2025	Maike Schneider	<u>PHARMACOLOGICAL DOSE OF ATORVASTATIN INDUCES INFLAMMASOME ACTIVATION IN HUMAN MONOCYTES</u>
05 May 2025	Barbara Šernek	<u>EFFECT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS ON VASCULAR WALL INFLAMMATION PARAMETERS</u>
05 May 2025	Vasily Sukhorukov	<u>IMMUNE RESPONSE IN MONOCYTE-LIKE CYBRIDS WITH ATHEROSCLEROSIS-RELATED MITOCHONDRIAL MUTATIONS</u>
05 May 2025	Eveline Van Doorn	<u>SEX-SPECIFIC DIFFERENCES IN INNATE IMMUNE PHENOTYPE IN AORTIC STENOSIS</u>
05 May 2025	Yuzhe Weng	<u>LOW-DOSE IL-2 PROMOTES A TREG-DEPENDENT B CELL IMMUNOGLOBULIN CLASS SWITCH IN ATHEROSCLEROSIS</u>

Notable Presentations information at EAS 2025

Inflammation and Immune Mechanisms (4/4)



Date	Author	Title
05 May 2025	Daria Borodko	<u>CHRONIC INFLAMMATORY DISEASE: WHO IS RESPONSIBLE FOR NON-TOLERANT REACTION?</u>
05 May 2025	Natalie Fournier	<u>EICOSAPENTAENOIC ACID (EPA) REDUCES ABCA1 AND SR-BI CHOLESTEROL EFFLUX PATHWAYS FROM CHOLESTEROL-LOADED HUMAN THP-1 MACROPHAGES WITHOUT AFFECTING THE CELL PHENOTYPE</u>
05 May 2025	Raquel Griñán	<u>MIR-30D-5P CONTROLS HYPERHOMOCYSTEINEMIA-RELATED ATHEROSCLEROSIS THROUGH THE REGULATION OF TIMP3 AND MMP9</u>

Notable Presentations information at EAS 2025

Other studies (1/2)



Date	Author	Title
05 May 2025	Alessia Cipollone	<u>EFFICACY AND SAFETY OF MONOCLONAL ANTIBODIES AGAINST PCSK9I: REAL LIFE DATA</u>
05 May 2025	Luka Prgomet	<u>CLINICAL INERTIA IN DYSLIPIDEMIA AND HYPERTENSION TREATMENT - RESULTS FROM THE NATIONWIDE STUDY EHUH-2 (CROATIA) - PRELIMINARY FINDINGS</u>
05 May 2025	Mircea-Vasile Milaciu	<u>ARTERIAL STIFFNESS MEASUREMENTS IN A VULNERABLE ROMANIAN POPULATION: PARTIAL RESULTS FROM THE MELVIN PROJECT</u>
05 May 2025	Fatema Abdullah	<u>HIGH-FAT DIET INTENSIFY RENAL FIBROSIS INDEPENDENT OF HYPERTENSION THROUGH TGFB AND PDGF SIGNALING: RESULTS FROM HYPERTENSIVE RAT STRAINS</u>
05 May 2025	John Kastelein	<u>EFFICACY AND SAFETY OF COMBINATION OBICETRAPIB WITH MODERATE-DOSE STATINS</u>
05 May 2025	Ayoub Salehi	<u>STUDYING THE EFFICACY OF LOW DOSE COLCHICINE ON CLINICAL OUTCOMES OF PATIENTS WITH STEMI: A RANDOMIZED CONTROLLED TRIAL.</u>
05 May 2025	Luke Gamon	<u>SPATIAL PROTEOMICS OF THE HUMAN ATHEROSCLEROTIC MICROENVIRONMENT REVEALS HETEROGENEITY IN INTRA-PLAQUE PROTEOMES AND EXTRACELLULAR MATRIX REMODELING</u>
05 May 2025	Aarif Khakoo	<u>POTENT, DURABLE, AND SAFE LDLC REDUCTION IN NON-HUMAN PRIMATES WITH A NOVEL CRISPR-BASED EPIGENETIC SILENCER AT THERAPEUTICALLY RELEVANT DOSES</u>
05 May 2025	Xiao-Yu Tian	<u>OSCILLATORY SHEAR STRESS REGULATES STRESS GRANULE DYNAMICS AND ITS INTERACTION WITH PPARD DURING ATHEROGENESIS</u>

Notable Presentations information at EAS 2025

Other studies (2/2)



Date	Author	Title
05 May 2025	Sander Eens	<u>DOXORUBICIN PROMOTES ATHEROSCLEROSIS IN AN APOLIPOPROTEIN E-DEFICIENT MOUSE MODEL, POTENTIALLY ASSOCIATED WITH SERPINA3N</u>
06 May 2025	Laura Alonso-Herranz	<u>SMAD7 DELETION IN SMOOTH MUSCLE CELLS PROMOTES THE CONTRACTILE PHENOTYPE AND RESULTS IN MORE STABLE ATHEROSCLEROTIC PLAQUES</u>
06 May 2025	Daniel M. Clemens	<u>A PHASE 1 TRIAL OF UDP-003, A THERAPEUTIC TO REVERSE ATHEROSCLEROSIS BY THE SPECIFIC REMOVAL OF 7-KETOCHOLESTEROL</u>
7 May 2025	Brian A. Ference	<u>SAFETY AND EFFICACY OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION: FROM GENETICS TO OUTCOME TRIALS</u>



Key Industry Sponsored Sessions Information



EAS 2025 Key Industry Sponsored Sessions Information (1/3)

Date	Sponsor	Title
04 May 2025	Menarini Group	<u>NEW TREATMENT OPTIONS IN DYSLIPIDEMIA, FROM BASIC SCIENCE TO CLINICAL EVIDENCE</u>
		<u>UNMET NEEDS IN LIPIDOLOGY</u>
		<u>THE BIOLOGICAL BASIS OF CETP INHIBITION</u>
		<u>POTENTIAL ROLE OF CETPI IN CARDIOMETABOLIC RISK</u>
05 May 2025	Ultragenyx	<u>OPTIMIZING THE DIAGNOSIS AND TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH)</u>
		<u>HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH): AETIOLOGY, PRESENTATION AND DIAGNOSIS THROUGH THE LENS OF THE HICC REGISTRY – WHERE ARE THE 'MISSING' PATIENTS?</u>
		<u>EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOFH: A REVIEW OF THE CLINICAL DATA IN ADULT, ADOLESCENT AND PAEDIATRIC PATIENTS</u>

EAS 2025 Key Industry Sponsored Sessions Information (2/3)



Date	Sponsor	Title
05 May 2025	Ultragenyx	<u>CLINICAL EXPERIENCE WITH EVINACUMAB AT EVELINA LONDON CHILDREN'S HOSPITAL</u>
06 May 2025	Amarin	<u>CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL: ARE WE STILL MISSING THE LINK?</u>
		<u>CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL IN REDUCE-IT</u>
		<u>EPA'S MECHANISM OF ACTION: CONNECTING THE DOTS</u>
		<u>BEYOND GUIDELINES – INTEGRATING EMERGING EVIDENCE</u>
06 May 2025	Daiichi Sankyo	<u>ADVANCING LIPID MANAGEMENT: INSIGHTS FROM REAL-WORLD EVIDENCE AND COMBINATION THERAPY TRIALS</u>
		<u>TOWARDS GOAL ATTAINMENT: EXPLORING ORAL LIPID-LOWERING STRATEGIES FOR HIGH-RISK PATIENTS</u>





EAS 2025 Key Industry Sponsored Sessions Information (3/3)

Date	Sponsor	Title
06 May 2025	Daiichi Sankyo	<u>COMPARATIVE REAL-WORLD OUTCOMES ACROSS EUROPEAN COUNTRIES: INSIGHTS FROM THE MILOS STUDY</u>
06 May 2025	Chiesi	<u>GETTING TO THE HEART OF THE MATTER: OPTIMISING LONG-TERM PATIENT OUTCOMES IN ADULT HOFH</u>
		<u>USING REAL-WORLD EVIDENCE TO BETTER UNDERSTAND DISEASE BURDEN IN HOFH</u>
		<u>TREATING TO TARGET: ACHIEVING LDL-C GOALS IN HOFH</u>
		<u>PATIENTS AT THE HEART OF UK HOFH CARE</u>



Noteworthy AI / ML presentations at EAS 2025





Themes from key AI / ML presentations at EAS 2025 (1/2)

- **At EAS 2025, AI and machine learning are transforming cardiovascular care through advanced risk stratification, precision imaging, and personalized prevention—leveraging real-world data, deep learning models, and digital health platforms to optimize patient outcomes**
- Check out the key AI / ML themes at EAS 2025 below:
- **Risk Stratification and Predictive Modeling:**
 - AI was used to predict long-term cardiovascular risk in the ATTICA study (20-year data) and for dyslipidemia detection, enabling proactive patient segmentation and therapy planning
- **AI-Driven Imaging Enhancements:**
 - Deep learning models improved segmentation of coronary and perivascular anatomy, enhancing diagnostic accuracy in CTA and guiding treatment in stable angina using AI-based FAI scoring
- **Machine Learning in Coronary Disease Diagnosis:**
 - AI tools predicted coronary artery stenosis and identified lesions in angiography, reducing unnecessary procedures and supporting cost-effective clinical decision-making



Themes from key AI / ML presentations at EAS 2025 (2/2)

- **Personalized Prevention Through Digital Health:**

- AI-powered platforms and digital health solutions enabled tailored prevention strategies, leveraging real-world data and omics profiling for individualized cardiovascular risk reduction

- **AI in Multimodal Disease Characterization:**

- Studies applied AI to phenotype atherosclerosis, analyze coronary plaque volume, and assess cardio-atherogenic risk in early Parkinson's using radiological and biochemical variables



Noteworthy AI / ML presentations at EAS 2025

Notable Presentations At EAS 2025

AI / ML (1/2)



Date	Author	Title
05 May 2025	Anastassia Anastassopoulou	<u>ARTIFICIAL INTELLIGENCE-POWERED APPROACHES FOR REAL-WORLD EVIDENCE RESEARCH CHALLENGES IN LIPID MANAGEMENT: A NARRATIVE REVIEW</u>
05 May 2025	Ikboljon Sobirov	<u>A NOVEL DEEP LEARNING MODEL FOR ENHANCED SEGMENTATION OF INTERNAL MAMMARY ARTERY, AORTA AND THEIR PERIVASCULAR REGIONS</u>
05 May 2025	Jamol Uzokov	<u>THE ROLE OF ARTIFICIAL INTELLIGENCE IN IDENTIFYING CORONARY ARTERY LESIONS IN CORONARY ANGIOGRAPHY</u>
05 May 2025	Nerea Sanfeliu Garces	<u>THE UTILITY OF FAT ATTENUATION INDEX (FAI) AND AI-SCORING IN CHANGING MANAGEMENT OF STABLE ANGINA: A RETROSPECTIVE ANALYSIS</u>
05 May 2025	Nadiia Demikhova	<u>ASSESSMENT OF RISK FACTORS DURING CARDIOSURGICAL INTERVENTIONS USING ARTIFICIAL CIRCULATION</u>
05 May 2025	Minkyung Lee	<u>PREDICTION OF DYSLIPIDEMIA USING MACHINE LEARNING TECHNIQUES</u>
05 May 2025	Myra Tilney	<u>CONTEXTUAL CO-DESIGN OF A CASCADE TESTING APPROACH IN FH: QUALITATIVE STUDY OF STAKEHOLDER PERSPECTIVES TO INFORM COMMUNICATION STRATEGY IN A CHANGING DIGITAL ENVIRONMENT</u>
05 May 2025	Frank Annie	<u>COMPARISON OF CORONARY PLAQUE VOLUME IN A HIGH-RISK POPULATION USING AI-BASED QUANTITATIVE CORONARY PLAQUE ANALYSIS</u>
05 May 2025	John Deanfield	<u>DIGITAL HEALTH SOLUTIONS FOR PERSONALISED PREVENTION</u>

Notable Presentations At EAS 2025

AI / ML (2/2)



Date	Author	Title
05 May 2025	Kenneth Chan	NOVEL AI TECHNOLOGY TO QUANTIFY CORONARY INFLAMMATION AND CARDIOVASCULAR RISK WITH ROUTINE CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY: A COST-EFFECTIVENESS ANALYSIS
05 May 2025	Andreas Leiherer	PREDICTING CORONARY ARTERY STENOSIS USING MACHINE LEARNING TO REDUCE UNNECESSARY ANGIOGRAPHIES
06 May 2025	Calum Macrae	USING AI TO UTILISE DIGITAL INFORMATION IN CLINICAL PRACTICE
06 May 2025	Fotios Barkas	PREDICTING LONG-TERM CARDIOVASCULAR RISK USING MACHINE LEARNING: 20-YEAR DATA FROM THE ATTICA STUDY
06 May 2025	Joseph Wu	STEM CELLS, GENOMICS, AND AI FOR DRUG DISCOVERY
07 May 2025	Thomas F. Luscher	WILL AI CURE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
07 May 2025	Ron Blankstein	ATHEROSCLEROSIS PHENOTYPING USING ARTIFICIAL INTELLIGENCE: IMPLICATIONS FOR IMAGING
07 May 2025	Manuel Mayr	GAIN UNPRECEDENTED INSIGHTS INTO CVD WITH THE LATEST -OMICS TECHNOLOGIES USING GENERATIVE AI
Virtual	Esra Demir Unal	CARDIO-ATHEROGENIC RISK ANALYSIS IN EARLY-STAGE IDIOPATHIC PARKINSON'S DISEASE USING MACHINE LEARNING MODELING METHODS BASED ON RADIOLOGICAL AND BIOCHEMICAL VARIABLES

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VAUAINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM